10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2022

CONSOLIDATED STATEMENTS OF INCOME

Period Ending Dec 31, 2022 10-K (Filed: Feb 22, 2023)

(In Millions)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2022Dec 31, 2021Dec 31, 2020
Revenues:
Total revenues
$
27,281
27,30524,689
Costs and expenses:
Cost of goods sold5,6576,6014,572
Research and development expenses4,9774,6014,927
Acquired in-process research and development expenses9449395,968
In-process research and development impairment2,70000
Selling, general and administrative expenses5,6735,2465,151
Total costs and expenses19,95117,38720,618
 
Operating income7,3309,9184,071
 
Interest expense(935)(1,001)(984)
Other income (expense), net(581)(639)(1,418)
Income before income taxes5,8148,2781,669
 
Income tax expense(1,248)(2,077)(1,580)
Net income4,5666,20189
 
Net loss attributable to noncontrolling interest262434
Net income attributable to Gilead4,5926,225123
 
Basic earnings per share attributable to Gilead (in dollars per share)3.664.960.10
Shares used in basic earnings per share attributable to Gilead calculation (in shares)1,2551,2561,257
Diluted earnings per share attributable to Gilead (in dollars per share)3.644.930.10
Shares used in diluted earnings per share attributable to Gilead calculation (in shares)1,2621,2621,263
Product and Service
Product sales
Total revenues26,98227,00824,355
Royalty, contract and other revenues
Total revenues299297334
External Links 
GILEAD SCIENCES, INC. (GILD) Fiscal Year 2022
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip